Novartis AG NVSEF OTC · Healthcare · Switzerland
$162.12 +0.00% +$0.00
Summary
69 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 18 USD is left as net profit.
- It earns 14 USD a year on every 100 USD of invested capital.
- It has raised its dividend 6 years in a row.
- It bought back its own shares for $9.65B in the last fiscal year, 3.2% of its market value.
What to watch
- It missed profit estimates 5 times in the last 8 quarters.
- You pay 31.0 USD for 1 USD of yearly profit, a lot for its sector.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBy our assumptions the price matches the value of the business: the two differ by less than 10 %.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 31.0 USD for 1 USD of yearly profit. Over the last five years it was 16.8 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 2.7% a year over 5 years. Over the last 3 years it grew by 3.3% a year. For the next fiscal year analysts expect revenue to grow by 0.1%.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 26 USD
- Research and development 21 USD
- Sales and administration 23 USD
- Taxes and other 13 USD
- Net profit 18 USD
Net profit, industry median (Drug Manufacturers - General) 14 USD
Out of every 100 USD of revenue, 18 USD is left as net profit.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 3.2 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, at risk- Yield
- 2.92%
- Paid out of profit
- 91%
- Raised in a row
- 6 years
You receive $4.74 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Neutral- Buy 5
- Hold 14
- Sell 1
No analyst has published a price target.
25% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
The company reports no revenue by product.
By region
- CHINA 52%
- GERMANY 48%
CHINA brings in 52% of revenue.
Segments in detail